ENDRA Life Sciences
NDRA

$0.2113

7.37%

Market Cap: $3.65M

About: ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Employees: 21

Healthcare Electromedical & Electrotherapeutic Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

15% more funds holding

Funds holding: 13 [Q1] → 15 (+2) [Q2]

1.25% less ownership

Funds ownership: 2.39% [Q1] → 1.14% (-1.25%) [Q2]

49% less capital invested

Capital invested by funds: $153K [Q1] → $77.7K (-$75.5K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NDRA.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about NDRA published over the past 30 days

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To regain compliance.

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2024 Earnings Conference Call August 22, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Alexander Tokman - Acting CEO Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Richard Jacroux - CFO Conference Call Participants Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.

ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update: New executive team Subsequent to quarter-end, ENDRA announced leadership changes. Board member Alexander Tokman was appointed as acting CEO, bringing 24+ years of global commercial leadership experien.

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Announces Reverse Stock Split

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to tra.

ENDRA Life Sciences Announces Reverse Stock Split

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as reg.

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

ENDRA Life Sciences Announces Leadership Changes

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors. The Company also announced the addition to its senior management team of Ziad Rouag as Head o.

ENDRA Life Sciences Announces Leadership Changes

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate develop.

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today?

ENDRA Life Sciences (NASDAQ: NDRA ) stock is up on Monday after the clinical diagnostic ultrasound technology company revealed an investment from S.H.N. Financial Investments Ltd.

Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today?

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. The offering is.

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

See News Rankings